Federal Register / Vol. 89, No. 190 / Tuesday, October 1, 2024 / Notices 79923 

services, and aged 21–64 years for 

cervical cancer services; and under- or 

uninsured. 

CDC proposes revisions to three of the 

previously approved information 

collection instruments: 

Annual NBCCEDP Survey—This 

instrument collects program-level 

information annually to monitor 

recipients’ challenges, external funding 

sources, partnerships, and EBI 

implementation. The survey has been 

revised to include new survey questions 

to improve data quality for items related 

to partnership activities and recipients’ 

requirements for patients’ payments 

towards screening services, as well as 

the removal of a COVID–19 related 

question. 

Clinic-Level Data Collection Tool— 

This instrument collects clinic-level 

data at baseline and annually to assess 

health system, clinic, and patient 

population characteristics; monitoring 

and quality improvement activities; EBI 

implementation; and baseline or annual 

screening rates. This tool has been 

revised to remove COVID–19 related 

variables and update response options 

for the measures used to report breast 

and cervical cancer screening rates. 

QPU—This instrument collects 

program-level data four times per year 

to monitor award spending, service 

delivery, staff vacancies, program 

challenges and successes, and TA 

needs. This instrument has been revised 

to include two optional open-ended 

items to allow recipients to provide 

context to reported service delivery and 

spending data only if needed. 

CDC proposes continued use of the 

remaining two information collections; 

Service Delivery Project Worksheet and 

the MDEs, which have not been 

changed. To maximize consistency in 

our routine data collections for the 

current NBCCEDP funding cycle, CDC 

has not revised NBCCEDP information 

collections to align with the Department 

of Health and Human Services (HHS)’ 

current best practices for demographic 

questions related to sexual orientation 

and gender identity (SOGI) and race and 

ethnicity (R/E) at this time. However, 

CDC plans to revise information 

collections that include demographic 

items to align with HHS’ SOGI and R/ 

E guidelines for the next funding cycle 

beginning in 2027. 

The proposed information collections 

will allow CDC to better gauge progress 

in meeting NBCCEDP program goals and 

monitor implementation activities, 

evaluate outcomes, and identify 

awardee technical assistance needs. In 

addition, findings will inform program 

improvement and help identify 

successful activities that need to be 

maintained, replicated, or expanded. 

OMB approval is requested for three 

years. CDC requests OMB approval for 

an estimated 1,162 annual burden 

hours. Participation is required for 

NBCCEDP awardees. There are no costs 

to respondents other than their time. 

ESTIMATED ANNUALIZED BURDEN HOURS

Type of respondents Form name Number of 

respondents 

Number of 

responses per 

respondent 

Average 

burden per 

response 

(in hours) 

Total burden 

(in hours) 

NBCCEDP Awardees ....................... Annual NBCCEDP Survey ............... 71 1 46/60 54 

NBCCEDP Clinic-level Information 

Collection Instrument—Breast.

71 6 40/60 284 

NBCCEDP Clinic-level Information 

Collection Instrument—Cervical.

71 6 40/60 284 

Quarterly Program Update ............... 71 4 22/60 151 

Service Delivery Projection Worksheet.71 1 29/60 34 

MDEs ................................................ 71 2 150/60 355 

Total ........................................... ........................................................... ........................ ........................ ........................ 1,162 

Jeffrey M. Zirger, 

Lead, Information Collection Review Office, 

Office of Public Health Ethics and 

Regulations, Office of Science, Centers for 

Disease Control and Prevention. 

[FR Doc. 2024–22477 Filed 9–30–24; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

[60Day—24–24IW; Docket No. CDC–2024– 

0070] 

Proposed Data Collection Submitted 

for Public Comment and 

Recommendations 

AGENCY: Centers for Disease Control and 

Prevention (CDC), Department of Health 

and Human Services (HHS). 

ACTION: Notice with comment period. 

SUMMARY: The Centers for Disease 

Control and Prevention (CDC), as part of 

its continuing effort to reduce public 

burden and maximize the utility of 

government information, invites the 

general public and other federal 

agencies the opportunity to comment on 

a proposed information collection, as 

required by the Paperwork Reduction 

Act of 1995. This notice invites 

comment on a proposed information 

collection project titled Becton 

Dickinson BACTECTM Blood Culture 

Media Bottles Shortage Impact 

Questionnaire, which will assess the 

impact of the Becton Dickinson (BD) 

BACTECTM blood culture media bottles 

supply shortage on individual facilities 

and how CDC NHSN bloodstream 

infection surveillance might be affected. 

DATES: CDC must receive written 

comments on or before December 2, 

2024. 

ADDRESSES: You may submit comments, 

identified by Docket No. CDC–2024– 

0070 by either of the following methods: 

• Federal eRulemaking Portal: 

www.regulations.gov. Follow the 

instructions for submitting comments. 

• Mail: Jeffrey M. Zirger, Information 

Collection Review Office, Centers for 

Disease Control and Prevention, 1600 

Clifton Road NE, MS H21–8, Atlanta, 

Georgia 30329. 

Instructions: All submissions received 

must include the agency name and 

Docket Number. CDC will post, without 

change, all relevant comments to 

www.regulations.gov. 

Please note: Submit all comments 

through the Federal eRulemaking portal 

(www.regulations.gov) or by U.S. mail to 

the address listed above. 


khammond on DSKJM1Z7X2PROD with NOTICES
79924 Federal Register / Vol. 89, No. 190 / Tuesday, October 1, 2024 / Notices 

FOR FURTHER INFORMATION CONTACT: To 

request more information on the 

proposed project or to obtain a copy of 

the information collection plan and 

instruments, contact Jeffrey M. Zirger, 

Information Collection Review Office, 

Centers for Disease Control and 

Prevention, 1600 Clifton Road NE, MS 

H21–8, Atlanta, Georgia 30329; 

Telephone: 404–639–7570; Email: omb@

cdc.gov. 

SUPPLEMENTARY INFORMATION: Under the 

Paperwork Reduction Act of 1995 (PRA) 

(44 U.S.C. 3501–3520), federal agencies 

must obtain approval from the Office of 

Management and Budget (OMB) for each 

collection of information they conduct 

or sponsor. In addition, the PRA also 

requires federal agencies to provide a 

60-day notice in the Federal Register 

concerning each proposed collection of 

information, including each new 

proposed collection, each proposed 

extension of existing collection of 

information, and each reinstatement of 

previously approved information 

collection before submitting the 

collection to the OMB for approval. To 

comply with this requirement, we are 

publishing this notice of a proposed 

data collection as described below. 

The OMB is particularly interested in 

comments that will help: 

1. Evaluate whether the proposed 

collection of information is necessary 

for the proper performance of the 

functions of the agency, including 

whether the information will have 

practical utility; 

2. Evaluate the accuracy of the 

agency’s estimate of the burden of the 

proposed collection of information, 

including the validity of the 

methodology and assumptions used; 

3. Enhance the quality, utility, and 

clarity of the information to be 

collected; 

4. Minimize the burden of the 

collection of information on those who 

are to respond, including through the 

use of appropriate automated, 

electronic, mechanical, or other 

technological collection techniques or 

other forms of information technology, 

e.g., permitting electronic submissions 

of responses; and 

5. Assess information collection costs. 

Proposed Project 

National Healthcare Safety Network 

(NHSN) Becton Dickinson BACTECTM

Blood Culture Media Bottles Shortage 

Impact Questionnaire—New—National 

Center for Emerging and Zoonotic 

Infection Diseases (NCEZID), Centers for 

Disease Control and Prevention (CDC). 

Background and Brief Description 

The Division of Healthcare Quality 

Promotion (DHQP), National Center for 

Emerging and Zoonotic Infectious 

Diseases (NCEZID), Centers for Disease 

Control and Prevention (CDC) collects 

data from healthcare facilities in the 

National Healthcare Safety Network 

(NHSN) under OMB Control No. 0920– 

0666. NHSN provides facilities, health 

departments, states, regions, and the 

nation with data necessary to identify 

problem areas, measure the progress of 

prevention efforts, and ultimately 

eliminate healthcare-associated 

infections (HAIs) nationwide. NHSN 

also allows healthcare facilities to track 

blood safety errors and various HAI 

prevention practice methods such as 

healthcare personnel influenza vaccine 

status and corresponding infection 

control adherence rates. Enrollment in 

NHSN has continuously increased, with 

over 37,000 actively reporting 

healthcare facilities across the U.S. Of 

the total enrolled healthcare facilities, 

there are over 6,000 acute care facilities. 

NHSN currently has eight components, 

and the collection of information is 

authorized by the Public Health Service 

Act (42 U.S.C. 242b, 242k, and 242m 

(d)). 

Data reported under NHSN’s Patient 

Safety Component are used to determine 

the magnitude of the healthcareassociated adverse events and trends in 

the rates of the events, in the 

distribution of pathogens, and in the 

adherence to prevention practices. Data 

will help detect changes in the 

epidemiology of adverse events 

resulting from new medical therapies 

and changing patient risks. 

Additionally, reported data is being 

used to describe the epidemiology of 

antimicrobial use and resistance and to 

better understand the relationship of 

antimicrobial therapy to this rising 

problem. 

NHSN’s data is used to aid in the 

tracking of HAIs and guide infection 

prevention activities/practices that 

protect patients. The Centers for 

Medicare and Medicaid Services (CMS) 

and other payers use these data to 

determine incentives for performance at 

healthcare facilities across the US and 

surrounding territories, and members of 

the public may use some protected data 

to inform their selection among 

available providers. Each of these 

parties is dependent on the 

completeness and accuracy of the data. 

CDC and CMS work closely and are 

fully committed to ensuring complete 

and accurate reporting, which are 

critical for protecting patients and 

guiding national, state, and local 

prevention priorities. 

The U.S. Food and Drug 

Administration (FDA) posted an 

announcement regarding interruptions 

in the supply of Becton Dickinson (BD) 

BACTEC (TM) blood culture media 

bottles because of recent supplier issues. 

The disruption in the supply is 

expected to impact patient diagnosis, 

follow-up patient management, and 

antimicrobial stewardship efforts. The 

FDA and other entities recommend that 

facilities, laboratories, and health care 

providers consider conservation 

strategies to prioritize the use of blood 

culture media bottles, preserving the 

supply for patients at highest risk. This 

information collection request includes 

a new data collection instrument that 

will assess the impact of the supply 

shortage on individual facilities and 

how CDC NHSN bloodstream infection 

surveillance might be affected. Facilities 

enrolled in the NHSN Patient Safety 

Component will be asked questions 

regarding the impact of the Becton 

Dickinson (BD) BACTEC (TM) blood 

culture media bottles for their facility. 

The questions will be collected 

electronically via the NHSN application. 

CDC requests OMB approval for an 

estimated 2,334 annual burden hours. 

There are no cost to respondents other 

than their time to participate. 

ESTIMATED ANNUALIZED BURDEN HOURS

Type of respondents Form name Number of 

respondents 

Number of 

responses 

per 

respondent 

Average 

burden per 

response 

(in hours) 

Total 

burden 

(in hours) 

Infection Preventionist/Microbiologist Blood Culture Bottle Shortage 

Questionnaire (Jul–Oct).

3,500 1 20/60 1,167 

Infection Preventionist/Microbiologist Blood Culture Bottle Shortage 

Questionnaire (Nov–Mar).

3,500 1 20/60 1,167 


khammond on DSKJM1Z7X2PROD with NOTICES
Federal Register / Vol. 89, No. 190 / Tuesday, October 1, 2024 / Notices 79925 

ESTIMATED ANNUALIZED BURDEN HOURS—Continued 

Type of respondents Form name Number of 

respondents 

Number of 

responses 

per 

respondent 

Average 

burden per 

response 

(in hours) 

Total 

burden 

(in hours) 

Total ........................................... ........................................................... ........................ ........................ ........................ 2,334 

Jeffrey M. Zirger, 

Lead, Information Collection Review Office, 

Office of Public Health Ethics and 

Regulations, Office of Science, Centers for 

Disease Control and Prevention. 

[FR Doc. 2024–22475 Filed 9–30–24; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

[60Day–24–24IV; Docket No. CDC–2024– 

0071] 

Proposed Data Collection Submitted 

for Public Comment and 

Recommendations 

AGENCY: Centers for Disease Control and 

Prevention (CDC), Department of Health 

and Human Services (HHS). 

ACTION: Notice with comment period. 

SUMMARY: The Centers for Disease 

Control and Prevention (CDC), as part of 

its continuing effort to reduce public 

burden and maximize the utility of 

government information, invites the 

general public and other federal 

agencies the opportunity to comment on 

a proposed information collection, as 

required by the Paperwork Reduction 

Act of 1995. This notice invites 

comment on a proposed information 

collection project titled 

‘‘Comprehensive Evaluation of the 

Implementation and Uptake of the CDC 

Clinical Practice Guideline for 

Prescribing Opioids for Pain’’. This data 

collection is designed to allow CDC to 

evaluate the 2022 CDC Clinical Practice 

Guidelines for opioid prescription 

practices. 

DATES: CDC must receive written 

comments on or before December 2, 

2024. 

ADDRESSES: You may submit comments, 

identified by Docket No. CDC–2024– 

0071 by either of the following methods: 

• Federal eRulemaking Portal: 

www.regulations.gov. Follow the 

instructions for submitting comments. 

• Mail: Jeffrey M. Zirger, Information 

Collection Review Office, Centers for 

Disease Control and Prevention, 1600 

Clifton Road NE, MS H21–8, Atlanta, 

Georgia 30329. 

Instructions: All submissions received 

must include the agency name and 

Docket Number. CDC will post, without 

change, all relevant comments to 

www.regulations.gov. 

Please note: Submit all comments 

through the Federal eRulemaking portal 

(www.regulations.gov) or by U.S. mail to 

the address listed above. 

FOR FURTHER INFORMATION CONTACT: To 

request more information on the 

proposed project or to obtain a copy of 

the information collection plan and 

instruments, contact Jeffrey M. Zirger, 

Information Collection Review Office, 

Centers for Disease Control and 

Prevention, 1600 Clifton Road NE, H 

21–8, Atlanta, Georgia 30329; 

Telephone: 404–639–7570; Email: omb@

cdc.gov. 

SUPPLEMENTARY INFORMATION: Under the 

Paperwork Reduction Act of 1995 (PRA) 

(44 U.S.C. 3501–3520), federal agencies 

must obtain approval from the Office of 

Management and Budget (OMB) for each 

collection of information they conduct 

or sponsor. In addition, the PRA also 

requires federal agencies to provide a 

60-day notice in the Federal Register 

concerning each proposed collection of 

information, including each new 

proposed collection, each proposed 

extension of existing collection of 

information, and each reinstatement of 

previously approved information 

collection before submitting the 

collection to the OMB for approval. To 

comply with this requirement, we are 

publishing this notice of a proposed 

data collection as described below. 

The OMB is particularly interested in 

comments that will help: 

1. Evaluate whether the proposed 

collection of information is necessary 

for the proper performance of the 

functions of the agency, including 

whether the information will have 

practical utility; 

2. Evaluate the accuracy of the 

agency’s estimate of the burden of the 

proposed collection of information, 

including the validity of the 

methodology and assumptions used; 

3. Enhance the quality, utility, and 

clarity of the information to be 

collected; 

4. Minimize the burden of the 

collection of information on those who 

are to respond, including through the 

use of appropriate automated, 

electronic, mechanical, or other 

technological collection techniques or 

other forms of information technology, 

e.g., permitting electronic submissions 

of responses; and 

5. Assess information collection costs. 

Proposed Project 

Comprehensive Evaluation of the 

Implementation and Uptake of the CDC 

Clinical Practice Guideline for 

Prescribing Opioids for Pain—New— 

National Center for Injury Prevention 

and Control (NCIPC), Centers for 

Disease Control and Prevention (CDC). 

Background and Brief Description 

Beginning in the 1990s, opioid 

prescribing rates for pain management 

steadily increased until 2010, remained 

steady until 2012, and have declined 

since then. The increase in opioid 

prescribing rates corresponded with 

increases in opioid-involved overdose 

deaths, which initially primarily 

involved prescription opioids (natural 

and semi-synthetic opioids and 

methadone). In response to this 

emerging crisis, CDC issued the CDC 

Guideline for Prescribing Opioids for 

Chronic Pain—United States, 2016 

(2016 CDC Guideline). Implementing 

the 2016 CDC Guideline was associated 

with reductions in opioid prescribing 

and increases in use of non-opioid 

medications for pain. At the same time, 

laws and policies related to prescribing 

opioids were instituted that misapplied 

or were inconsistent with the 2016 CDC 

Guideline, potentially contributing to 

patient harm. In 2022, CDC released the 

CDC Clinical Practice Guideline for 

Prescribing Opioids for Pain—United 

States, 2022, which provided up to date 

evidence regarding pain management 

approaches and re-emphasizes the need 

for prescribers to be focused on patientcentered care to provide effective pain 

management. CDC is comprehensively 

evaluating the uptake, implementation, 

and outcomes of the 2022 CDC Clinical 

Practice Guideline on evidence-based 

care for pain management to understand 

its impact. 


khammond on DSKJM1Z7X2PROD with NOTICES